Results 101 to 110 of about 357,544 (339)

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

How Taxol/paclitaxel kills cancer cells

Molecular Biology of the Cell, 2014
Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma.
Beth A. Weaver
semanticscholar   +1 more source

Swelling‐Programmed Topographical Guidance for Dynamic Spheroid Self‐Assembly via a Mechanochemical Hydrogel Niche

Advanced Functional Materials, EarlyView.
A swelling‐programmed micropatterned hydrogel guides adherent cells through a controlled transition from cell–matrix anchoring to cadherin‐mediated cell–cell compaction, enabling rapid assembly of high‐viability spheroids with defined size and morphology.
Han Gyeol Nam, Seon Yeong Chae, Young Woo Kwon, Hye Jin Heo, Hye Rin Lee, Ji Hyeok Lee, Dong‐Wook Han, Yun Hak Kim, Suck Won Hong   +8 more
wiley   +1 more source

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

International Journal of Nanomedicine, 2013
Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women.
Gupta N, Hatoum H, Dy GK
doaj  

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Journal of Clinical Oncology, 2018
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous ...
A. Fader, D. Roque, E. Siegel, N. Buza, P. Hui, O. Abdelghany, S. Chambers, A. Secord, L. Havrilesky, D. O’Malley, F. Backes, N. Nevadunsky, B. Edraki, D. Pikaart, W. Lowery, K. ElSahwi, P. Celano, S. Bellone, M. Azodi, B. Litkouhi, E. Ratner, D. Silasi, P. Schwartz, A. Santin   +23 more
semanticscholar   +1 more source

Small Extracellular Vesicles from Neural Cells: Physiological and Pathological Roles, and Potential in Neurodegenerative Therapy

Advanced Healthcare Materials, EarlyView.
Neural cell–derived small extracellular vesicles (sEVs) are emerging as pivotal mediators in neurodegenerative diseases, exerting both pathogenic and therapeutic functions. This review synthesizes current evidence on how sEVs from distinct neural cell types regulate neurodegeneration, neuroprotection, biomarker discovery, and targeted drug delivery ...
Muhammad Waqas Salim, Wei Zhang, Lyndsey Collins‐Praino, Yuling Wang, Andrew Care   +4 more
wiley   +1 more source

Proinflammatory Factors Mediate Paclitaxel-Induced Impairment of Learning and Memory

Mediators of Inflammation, 2018
The chemotherapeutic agent paclitaxel is widely used for cancer treatment. Paclitaxel treatment impairs learning and memory function, a side effect that reduces the quality of life of cancer survivors. However, the neural mechanisms underlying paclitaxel-
Zhao Li, Shuang Zhao, Hai-Lin Zhang, Peng Liu, Fei-Fei Liu, Yue-Xian Guo, Xiu-Li Wang   +6 more
doaj   +1 more source

FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter

Molecular Therapy: Oncolytics, 2019
FoxM1 amplification in human pancreatic cancer predicts poor prognosis and resistance to paclitaxel. Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.
Chao Huang, Xin Zhang, Li Jiang, Limin Zhang, Ming Xiang, Hongyu Ren   +5 more
doaj   +1 more source

Mapping Nanoscale Protein‐Corona Kinetics of DoE‐Optimized Perfluorocarbon Encapsulated‐PLGA Nanoparticles by In Situ, Time‐Resolved Synchrotron SAXS

Advanced Healthcare Materials, EarlyView.
A two‐phase workflow (OFAT screening followed by central composite design) maps how processing variables tune PFCE‐PLGA nanoparticle size, dispersity, surface charge, loading, and 19F‐MRI signal. In situ, time‐resolved synchrotron SAXS tracks albumin‐corona growth on intact dispersions and reveals PFCE‐dependent adsorption pathways.
Joice Maria Joseph, Maria Rosa Gigliobianco, Cristina Minnelli, Paolo Moretti, Francesco Spinozzi, Giovanna Mobbili, Sara Pistolesi, Cristina Casadidio, Gabriella Teti, Roberta Censi, Stefano Antonio Gattone, Piera Di Martino   +11 more
wiley   +1 more source

Drug Distribution and Stent Retention of Drug Eluting Stents [PDF]

, 2008
In this paper the examinations of drug eluting coronary stents are shown, such as the morphology of the coatings before expansion, drug distribution, the methodology and the value of stent retention.
Balázs, T., Bognár, Eszter, Dobránszky, János, Ring, Gy.   +3 more
core